Ginkgo Bioworks Holdings, Inc.
DNA
Positions held
Your positionsDNA isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $763.64M | Enterprise value | $865.59M | Trailing P/E | — | Forward P/E | -3.91 |
| PEG | — | Price / book | 1.72 | Beta | 1.80 | Dividend yield | 0.00% |
| Revenue growth | -48.5% | Earnings growth | — | Gross margin | 68.0% | Operating margin | -2.8% |
| Profit margin | -2.2% | ROE | -59.9% | ROA | -16.7% | Debt / equity | 0.96 |
| Current ratio | 4.57 | Free cash flow | -$72.40M | Analyst recommendation | none | Mean target | $7.00 |
| 52w high | $18.22 | 52w low | $5.37 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $20.2M | $19.5M | $33.4M | $38.8M | $39.1M | — |
| Op margin | -290.5% | -366.5% | -209.7% | -227.3% | -139.5% | — |
| Net income | -$46.7M | -$82.6M | -$80.8M | -$80.8M | -$60.3M | — |
| Gross margin | 91.5% | 84.1% | 78.1% | 67.0% | 86.3% | — |
| Gross profit | $18.4M | $16.4M | $26.1M | $26.0M | $33.8M | — |
| Operating income | -$58.5M | -$71.4M | -$70.0M | -$88.3M | -$54.6M | — |
- Revenue +4% vs prior quarter ($20M vs $19M).
- Gross margin 91.5% (was 84.1% prior quarter).
- Operating margin expanded to -290.5%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $170M | $227M | $251M | $478M | — |
| Op margin | -178.6% | -214.8% | -305.5% | -462.4% | — |
| Net income | -$313M | -$547M | -$893M | -$2.1B | — |
| Gross margin | 72.4% | 80.4% | 78.5% | 57.3% | — |
| Gross profit | $123M | $182M | $197M | $273M | — |
| Operating income | -$304M | -$488M | -$768M | -$2.2B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Ginkgo Bioworks to Provide Lab Access to NSF X-Labs Researchers
2026-10-08 · Ginkgo Bioworks, Araceli Biosciences Add Cellular Imaging to Autonomous Lab
2026-10-08 · Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula's Lab-in-the-Loop
2026-10-07 · Ginkgo Bioworks Holdings, Inc. (DNA) Falls More Steeply Than Broader Market: What Investors Need to Know
2026-10-05 · This Small-Cap Stock Announced a Deal With Eli Lilly. Then Its Shares Doubled
2026-10-01 · Ginkgo Bioworks Holdings, Inc. (DNA) Stock Falls Amid Market Uptick: What Investors Need to Know
2026-09-25 · What Needs To Be True To Buy Twist Bioscience Stock Now?
2026-09-23 · Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
2026-09-18 · Ginkgo Bioworks (DNA) Surges 11.1%: Is This an Indication of Further Gains?
2026-09-16 · Ginkgo Bioworks Holdings, Inc. (DNA) Rises As Market Takes a Dip: Key Facts
Price (daily)
Full chart · RSI · MACD · patterns